

4 December 2023

Fusion Antibodies plc
("Fusion" or the "Company")

Director/PDMR Shareholdings

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been notified of the following purchases of ordinary shares of 4 pence each in the Company ("**Ordinary Shares**") by certain Directors of Fusion.

Simon Douglas, Non-Executive Chair, has purchased 100,565 Ordinary Shares at an average price of 4.96 pence per share. Following this purchase, Simon Douglas directly holds 356,365 Ordinary Shares, representing approximately 0.60 per cent. of the Company's issued share capital.

Adrian Kinkaid, Chief Executive Officer, has purchased 101,847 Ordinary Shares at an average price of 4.90 pence per share. Following this purchase, Adrian Kinkaid holds 245,847 Ordinary Shares, representing approximately 0.41 per cent. of the Company's issued share capital.

Further details of the respective purchases are outlined in the tables below.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Simon Douglas	
2	Reason for the notification		
a)	Position/status	Non-Executive Chair	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Fusion Antibodies plc	
b)	LEI	213800KBAYRC9VOQ9V39	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	ordinary shares of 4p each in Fusion Antibodies plc	
	Identification code	Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16	
b)	Nature of the transaction	Purchase of Ordinary Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		4.96p	100,565
d)	Aggregated information - Aggregated volume - Price	- See above - See above	
e)	Date of the transaction	4 December 2023	
f)	Place of the transaction	XLON, London Stock Exchange	

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Adrian Kinkaid
2	Reason for the notification	
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification

3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Fusion Antibodies plc	
b)	LEI	213800KBAYRC9VOQ9V39	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	ordinary shares of 4p each in Fusion Antibodies plc	
	Identification code	Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16	
b)	Nature of the transaction	Purchase of Ordinary Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		4.90p	101,847
d)	Aggregated information - Aggregated volume - Price	- See above - See above	
e)	Date of the transaction	4 December 2023	
f)	Place of the transaction	XLON, London Stock Exchange	

Enquiries:

Fusion Antibodies plc
Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Chief Financial Officer

www.fusionantibodies.com
Via Walbrook PR

Allenby Capital Limited
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke (Sales and Corporate Broking)

Tel: +44 (0)20 3328 5656

Walbrook PR
Anna Dunphy

Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Mob: +44 (0)7876 741 001

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the discovery and development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody design, generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx™ platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at \$186 billion in 2021 and is forecast to surpass \$445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than \$3 bn in 2021.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFSDFELEDSEEE